Table 1.

Baseline Clinical Characteristics of Patients in the Randomized Population and the Pubertal Analysis Population

Pooled Treatment Group	Randomized Population, n = 149			Pubertal Analysis Population, n = 123
	Childhood Oral Placebo (n = 74)	Childhood Low-Dose Estrogen (n = 75)	P Valuea	Childhood Oral Placebo (n = 62)	Childhood Low-Dose Estrogen (n = 61)	P Valuea
Variable
Chronological age, y	7.5 (5.0 to 12.5)	8.5 (5.0 to 12.5)	.013	7.2 (5.0 to 11.9)	7.9 (5.0 to 11.9)	.035
Bone age, y	6.8 (2.0 to 13.0)	7.8 (2.5 to 12.0)	.076	6.0 (2.0 to 10.0)	6.8 (2.5 to 11.5)	.077
Bone age delay, y	−1.2 (−4.3 to 1.6)	−1.4 (−4.1 to 1.5)	.639	−1.3 (−3.7 to 1.6)	−1.3 (−4.1 to 1.5)	.957
Height SDS	−2.6 (−5.2 to −1.0)	−2.8 (−5.1 to −1.3)	.153	−2.5 (−5.2 to −1.0)	−2.7 (−4.6 to −1.4)	.426
Weight SDS	−1.4 (−5.0 to 2.9)	−1.6 (−4.2 to 2.1)	.270	−1.4 (−5.0 to 2.9)	−1.5 (−4.2 to 2.1)	.395
Body mass index SDS	0.6 (−4.0 to 3.3)	0.3 (−1.2 to 2.7)	.531	0.5 (−4.0 to 3.3)	0.3 (−1.2 to 2.7)	.640
45,X karyotype, %	76	71	.547	82	77	.663

Values shown are median (minimum to maximum). Childhood oral placebo group = oral placebo/placebo injection group + oral placebo/GH injection group; childhood low-dose estrogen group = childhood low-dose estrogen/placebo injection group + childhood low-dose estrogen/GH injection group; bone age delay = bone age minus chronological age; SDS = SD score.

^aP values are based on ANOVA models for continuous variables, and χ² test for percentage 45,X karyotype.